Overexpression of annexin A5 might guide the gemtuzumab ozogamicin treatment choice in patients with pediatric acute myeloid leukemia

BACKGROUND: Acute myeloid leukemia (AML) is a common hematological malignancy. Gemtuzumab ozogamicin (GO), a humanized anti-CD33 antibody conjugated with the potent anti-tumor antibiotic calicheamicin, represents a promising targeted therapy for AML. Annexin A5 (ANXA5) is a proposed marker for the c...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Ther Adv Med Oncol
Asıl Yazarlar: Zhang, Nan, Zhang, Ying, Zhang, Ping, Lou, Shifeng, Chen, Ying, Li, Huan, Zeng, Hanqing, Shen, Yan, Deng, Jianchuan
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: SAGE Publications 2020
Konular:
Original Research
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC7310896/
https://ncbi.nlm.nih.gov/pubmed/32636939
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/1758835920927635
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller